On May 12, 2026, Lantern Pharma Inc. entered into a securities purchase agreement to sell 1,454,175 shares at $2.06 each and pre-funded warrants, raising approximately $4.4 million for working capital. This event is significant as it aims to boost funding for their AI technology subsidiary and includes investor participation rights for future equity financing.